Literature DB >> 24356785

Treatment of functional (psychogenic) movement disorders.

Luciana Ricciardi1, Mark J Edwards.   

Abstract

Functional (psychogenic) movement disorders are a common source of disability and distress. Despite this, little systematic evidence is available to guide treatment decisions. This situation is likely to have been influenced by the "no man's land" that such patients occupy between neurologists and psychiatrists, often with neither side feeling a clear responsibility or ability to direct management. The aim of this narrative review is to provide an overview of the current state of the evidence regarding management of functional movement disorders. This reveals that there is some evidence to support the use of specific forms of cognitive behavioral therapy and physiotherapy. Such treatments may be facilitated in selected patients with the use of antidepressant medication, and may be more effective for those with severe symptoms when given as part of inpatient multidisciplinary rehabilitation. Other treatments, for example hypnosis and transcranial magnetic stimulation, are of interest, but further evidence is required regarding mechanism of effect and long-term benefit. Though prognosis is poor in general, improvement in symptoms is possible in patients with functional movement disorders, and there is a clear challenge to clinicians and therapists involved in their care to conduct and advocate for high-quality clinical trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24356785      PMCID: PMC3899472          DOI: 10.1007/s13311-013-0246-x

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  45 in total

1.  Imaging hypnotic paralysis: implications for conversion hysteria.

Authors:  P W Halligan; B S Athwal; D A Oakley; R S Frackowiak
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  What should we say to patients with symptoms unexplained by disease? The "number needed to offend".

Authors:  Jon Stone; Wojtek Wojcik; Daniel Durrance; Alan Carson; Steff Lewis; Lesley MacKenzie; Charles P Warlow; Michael Sharpe
Journal:  BMJ       Date:  2002-12-21

3.  Functional weakness: clues to mechanism from the nature of onset.

Authors:  Jon Stone; Charles Warlow; Michael Sharpe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-08-11       Impact factor: 10.154

4.  Patients' perceptions of medical explanations for somatisation disorders: qualitative analysis.

Authors:  P Salmon; S Peters; I Stanley
Journal:  BMJ       Date:  1999-02-06

5.  A randomised controlled clinical trial on the additional effect of hypnosis in a comprehensive treatment programme for in-patients with conversion disorder of the motor type.

Authors:  Franny C Moene; Philip Spinhoven; Kees A L Hoogduin; Richard van Dyck
Journal:  Psychother Psychosom       Date:  2002 Mar-Apr       Impact factor: 17.659

6.  Psychogenic dystonia.

Authors:  S Fahn; D T Williams
Journal:  Adv Neurol       Date:  1988

7.  Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms.

Authors:  H L Crimlisk; K Bhatia; H Cope; A David; C D Marsden; M A Ron
Journal:  BMJ       Date:  1998-02-21

8.  Hysterical neurosis of the conversion type: therapeutic activity of neuroleptics with different hyperprolactinemic potency.

Authors:  L Rampello; R Raffaele; G Nicoletti; F Le Pira; M Malaguarnera; F Drago
Journal:  Neuropsychobiology       Date:  1996       Impact factor: 2.328

9.  A randomized controlled clinical trial of a hypnosis-based treatment for patients with conversion disorder, motor type.

Authors:  Franny C Moene; Philip Spinhoven; Kees A L Hoogduin; Richard van Dyck
Journal:  Int J Clin Exp Hypn       Date:  2003-01

10.  Cognitive behavioural therapy for medically unexplained physical symptoms: a randomised controlled trial.

Authors:  A E Speckens; A M van Hemert; P Spinhoven; K E Hawton; J H Bolk; H G Rooijmans
Journal:  BMJ       Date:  1995-11-18
View more
  14 in total

1.  Functional movement disorder: a long journey to diagnosis.

Authors:  Sneha Bharadwaj; Melissa Lee; Andrew Campbell Moffat
Journal:  BMJ Case Rep       Date:  2015-08-28

2.  Editorial: Neurotherapeutics of movement disorders.

Authors:  Stewart A Factor; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Sharing notes with patients: A review of current practice and considerations for neurologists.

Authors:  Melissa M Yu; Allison L Weathers; Allan D Wu; David A Evans
Journal:  Neurol Clin Pract       Date:  2017-04

Review 4.  Psychogenic nonepileptic seizures and movement disorders: A comparative review.

Authors:  Roberto Erro; Francesco Brigo; Eugen Trinka; Giulia Turri; Mark J Edwards; Michele Tinazzi
Journal:  Neurol Clin Pract       Date:  2016-04

Review 5.  The most promising advances in our understanding and treatment of functional (psychogenic) movement disorders.

Authors:  Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2017-07-08       Impact factor: 4.891

Review 6.  Psychogenic nonepileptic seizures: a concise review.

Authors:  Ali A Asadi-Pooya
Journal:  Neurol Sci       Date:  2017-03-08       Impact factor: 3.307

7.  Paroxysmal non-kinesigenic dyskinesia, post-streptococcal syndromes and psychogenic movement disorders: a diagnostic challenge.

Authors:  Elena Peila; Paolo Mortara; Alessandro Cicerale; Lorenzo Pinessi
Journal:  BMJ Case Rep       Date:  2015-03-20

Review 8.  Functional (psychogenic) movement disorders - Clinical presentations.

Authors:  Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2015-09-03       Impact factor: 4.891

9.  Psychiatric Comorbidities in Functional Movement Disorders: A Retrospective Cohort Study.

Authors:  Zachary A Macchi; Isaiah Kletenik; Caroline Olvera; Samantha K Holden
Journal:  Mov Disord Clin Pract       Date:  2021-04-26

10.  Impact of Transcranial Magnetic Stimulation on Functional Movement Disorders: Cortical Modulation or a Behavioral Effect?

Authors:  Béatrice Garcin; Francine Mesrati; Cécile Hubsch; Thomas Mauras; Iulia Iliescu; Lionel Naccache; Marie Vidailhet; Emmanuel Roze; Bertrand Degos
Journal:  Front Neurol       Date:  2017-07-19       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.